T6117 |
Tivantinib
|
905854-02-6
|
99.95%
|
|
Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
|
T7900 |
BAY-474
|
1033767-86-0
|
99.89%
|
|
BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe
|
T2586 |
Cabozantinib
|
849217-68-1
|
99.88%
|
|
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Caboz...
|
T2894 |
Norcantharidin
|
5442-12-6
|
99.86%
|
|
Norcantharidin (Norcantharadine) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
|
T8825 |
Capmatinib 2HCl.H2O
|
1865733-40-9
|
99.84%
|
|
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
|
T25492 |
Hepln-13
|
64369-13-7
|
99.83%
|
|
Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
|
T5349 |
SCR-1481B1
|
1174161-86-4
|
99.83%
|
|
SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
|
T3209 |
AMG-337
|
1173699-31-4
|
99.82%
|
|
AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337(AMG337) inhibits MET kinase activity (IC50: < 5 nM...
|
T2419 |
BMS-794833
|
1174046-72-0
|
99.79%
|
|
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
|
TQ0041 |
Ningetinib Tosylate
|
1394820-77-9
|
99.77%
|
|
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
|
TQ0021 |
Ningetinib
|
1394820-69-9
|
99.77%
|
|
Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
|
T1963 |
Capmatinib
|
1029712-80-8
|
99.76%
|
|
Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
|
T13194 |
CSF1R-IN-2
|
2271119-26-5
|
99.71%
|
|
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
|
T8326 |
BMS-2
|
888719-03-7
|
99.7%
|
|
BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
|
T3113 |
Foretinib
|
849217-64-7
|
99.7%
|
|
Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
|
T8399 |
Crizotinib hydrochloride
|
1415560-69-8
|
99.67%
|
|
Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)
|
T2293 |
SGX-523
|
1022150-57-7
|
99.6%
|
|
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
|
T3455 |
Merestinib
|
1206799-15-6
|
99.56%
|
|
Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib...
|
T10655 |
C-Met inhibitor 1
|
1357072-61-7
|
99.56%
|
|
c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
|
T6094 |
MK-2461
|
917879-39-1
|
99.53%
|
|
MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an ave...
|